Strategic Advocates’s Amgen AMGN Stock Holding History

Strategic Advocates’s Portfolio AMGN Stock Details AMGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$8.44K	Buy	24 +3	+14%	+$1.07K	0.04%	162
2025 Q4	$6.9K	Hold	21	–	–	﹤0.01%	402
2025 Q3	$5.93K	Buy	+21	New	+$6.09K	﹤0.01%	396

Other funds holding AMGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Strategic Advocates's AMGN Position: Q1 2026 in Review

Strategic Advocates increased its Amgen (AMGN) stake by 14% in Q1 2026, buying an estimated $1.07K and bringing the position to 24 shares worth $8.44K. The position accounts for 0.04% of the portfolio, ranked #162.

Strategic Advocates first reported a position in AMGN in Q3 2025 and has held it in 3 quarters since. 3,128 funds tracked by Wall St. Rank hold AMGN as of Q1 2026.

Strategic Advocates held 24 shares of Amgen worth $8.44K as of Q1 2026.
Strategic Advocates bought 3 Amgen shares in Q1 2026, an estimated $1.07K.
Amgen made up 0.04% of Strategic Advocates's portfolio in Q1 2026, its #162 holding.
Strategic Advocates first reported a position in Amgen in Q3 2025 and has held it in 3 quarters since.
3,128 funds tracked by Wall St. Rank held Amgen as of Q1 2026.

Based on Strategic Advocates's 13F filing for Q1 2026, filed 15 May 2026.